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ABSTRACT
ACETALDEHYDE DEHYDROGENASE 2 (ALDH2) ACTIVATION PROTECTS HEPATOCYTES
FROM MITOCHONDRIAL DAMAGE AND DEATH CAUSED BY 4-HYDROXYNONENAL

Keegan J. Baldauf
August6,2012

Alcoholic liver disease (ALD) ranks among the major causes of morbidity and mortality in
the world and effects millions of patients each year. Progression of ALD is well characterized and
is actually a spectrum of liver diseases, which progresses from steatosis, to inflammation and
necrosis, to finally fibrosis and cirrhosis. However, the underlying mechanism(s) of ALD are not
as well understood, and as a result there is no FDA-approved therapy to prevent or reverse the
disease. With a better understanding of the mechanism(s) and risk factors that mediate the
initiation and progression of ALD, a targeted therapy can be developed to treat or prevent it. The
regenerative capacity of the liver is inhibited in fibrosis and cirrhosis. By enhancing the
regenerative ability of the liver we may be able to reverse the effects of ALD. Indeed, recent in
vivo studies by this group indicate that activating Aldehyde Dehydrogenase 2 (ALDH2) with Alda1 (a novel ALDH2 activator) or Ethanol (EtOH) protects against oxidative stress and damage to
the liver, as result enhancing regeneration. Because ALDH2 can protect mitochondria from
oxidative stress that results from partial hepatectomy, oxidative stress from other sources should
be protected against as well. To test this hypothesis, primary hepatocytes were isolated from
mice and plated on 96-well plates for analysis via Cellomics High Content Screening. Some mice
were administered EtOH for 3 days prior to hepatocyte isolation or exposed to Alda-1 to activate
ALDH2. Cells were exposed to 4-Hydroxynonenal (4-HNE; 0-1000 j.JM) for 0-24 H. Activation of
ALDH2, by pretreatment with EtOH or Alda-1 preexposure, clearly protected isolated hepatocytes
from 4-HNE toxicity. Mitochondrial membrane potential was significantly increased in cells with
IV

activated ALDH2 and membrane permeability was decreased in these cells as well. These
changes in hepatocyte viability indicate that activation of ALDH2 protects cells from oxidative
stress.
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INTRODUCTION

Alcoholic liver disease (ALD) ranks among the major causes of morbidity and mortality in the
world and affects millions of patients each year.

1

Progression of ALD is well characterized and is

actually a spectrum of liver diseases, from steatosis, to inflammation and necrosis, to finally
fibrosis and cirrhosis.
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However, the underlying mechanism(s) of ALD are not as well

understood, and as a result there is no FDA-approved therapy to prevent or reverse this disease.
With a better understanding of the mechanism(s) and risk factors that mediate the initiation and
progression of ALD, a targeted therapy can be developed to treat or prevent it.
The liver has tremendous regenerative capacity; which distinguishes it from other vital organs
(e.g., the brain, heart and lungs) which are not as readily able to replace functional tissue that has
been lost. In experimental models, the liver was able to regenerate from partial hepatectomy
(PHx) from 5 to 8 days in rodents.

3

Hepatocytes rarely proliferate in healthy adults but following

70% PHx, hepatocytes divide once or twice before returning to a quiescent state.

4

The ability of

the liver to regenerate is a process which requires interplay between several pathways
(cytokines, growth factors and metabolic networks).5 Changes in anyone of these pathways can
impair the ability of the liver to regenerate from injury. The regenerative capacity of the liver is
inhibited in fibrosis and cirrhosis.

6

Therefore, enhancing hepatic regeneration could be an

effective strategy to prevent the progression of ALD.
Aldehyde dehydrogenase 2 (ALDH2) is a mitochondrial enzyme that oxidizes acetaldehyde to
acetic acid, which is the final step in EtOH oxidationY A polymorphism of ALDH2 (ALDH2*2) is
a common variant with decreased activity. ALDH2*2 heterozygous individuals have significantly
higher acetaldehyde levels after ingestion of EtOH.

9

It is known that ALDH2 loss-of-function

polymorph isms increase the relative risk of developing ALD.

9

Given the known toxicity of

acetaldehyde, this risk association with alcohol consumption is not necessarily

surprising. However, the same polymorphism also increases the risk of development of other
chronic liver diseases [e.g., HCC and NAFLD 1Q ,11,12]. These data suggest that other factors
besides alcohol metabolism may contribute to the increased risk of the development of liver
disease in patients with the ALDH2 polymorphism.
In preliminary studies, our group has shown acute administration of ethanol activates ALDH2
which enhances hepatic regeneration (Figure 1). Furthermore, treatment with Alda-1, an ALDH2
activating compound, mimicked the effects of acute EtOH preexposure and treatment with
Daidzin (ALDH2 inhibitor) prevented the EtOH effect. These results support the hypothesis that
activation of ALDH2 enhances hepatic regeneration. Lipid peroxides are byproducts of PHx that
cause mitochondrial damage which can lead to blunted regeneration.
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It is hypothesized that

pretreatment with EtOH activates ALDH2 and attenuates the increased lipid peroxidation seen
following PHx in these studies. By elUCidating this mechanism we can develop new therapies
based on targeting ALDH2 to enhance hepatic regeneration.
To that end, we employed Cellomics Array Scan High Content Screening (HCS) to evaluate
this protective effect against hepatotoxicity induced by lipid aldehydes in isolated hepatocytes.
Cellomics HCS used a 96-well plate design to analyze cell parameters via fluorescent dyes and
allows for both visualization and quantification of the fluorescence. O'Brien et al reported that
using HCS they were able to predict hepatotoxicity sensitivity at 93% and specificity at 98% for
known compounds.

14

These results showed a marked increase in sensitivity from other

conventional cytotoxicity assays for human hepatotoxicity. The authors hypothesized most
cytotoxicity assays measure one endpoint, whereas there are many mechanisms for toxicity.
Cellomics HCS allows us to evaluate several parameters which include inner mitochondrial
membrane potential, cell membrane permeability and nuclear size that can be indicative of
hepatotoxicity. We employed this method to evaluate whether modifying ALDH2 activity would
alter the above mentioned parameters.
4-Hydroxynonenal (4-HNE) is a lipid aldehyde that is toxic to cells and studies have shown
that it is implicated in the pathogenesis of an extensive list of diseases including alcoholic liver
disease.

15

The lipid aldehyde is derived from n-6 polyunsaturated fatty acids (PUFAs) (e.g.,

2

linoleic acid, linolenic acid and arachidonic aCid).16 Metabolism of 4-HNE to 4-hydroxynon-2enoic acid (4HNA) is catalyzed by ALDH2; an enzyme which can also be inactivated by high
concentrations of 4_HNE.17,18 The inner mitochondrial membrane (IMM) is composed of a high
concentration of PUFAs which renders it susceptible to oxidative stress and the generation of 4HNE.19 By modulating the activity of ALDH2, thus altering metabolism of 4-HNE, we attempted to
build on the effects seen in our whole animal model previously.

3

MATERIALS AND METHODS

Animals and treatments

Male C57BLl6J mice (6-8 weeks old) were purchased from Jackson Laboratory (Bar
Harbor, ME). Mice were housed in a pathogen-free barrier facility accredited by the Association
for Assessment and Accreditation of Laboratory Animal Care, and procedures were approved by
the local Institutional Animal Care and Use Committee. Food and tap water were allowed ad
libitum.
In experiments designed to test the effects of EtOH on 4-HNE toxicity, 2 mice per group
were administered EtOH (6 mg/kg i.g. diluted in water) or, an isocaloric/isovolumetric contol,
Maltose-Dextrin (MD) for 3 days q.a.m. Hepatocytes from the mice were isolated 24 H after the
last i.g. dosing and seeded on 96 well plates (10,000 cells/well) for analysis by Cellomics HCS
(Fig. 2). The hepatocytes from each mouse were plated across 2 rows of the 96-well plate for
analysis. This allows duplicate wells from each mouse at each concentration of 4-HNE. In
experiments designed to test the protective effects of Alda-1 on 4-HNE exposure, hepatocytes
were isolated from mice and seeded on 96-well plates at a density of 10,000 cells/well (Fig. 2).
Each 96-well plate consisted of hepatocytes isolated from a single mouse for the Alda-1
experiments. To analyze the inhibitory effect of Daidzin on Alda-1-mediated activation of ALDH2
the plate design mirrored that of the Alda-1 experiments.

Partial Hepatectomy

Results in Figure 1 were from Ding et al (in publication) in which seventy percent partial
hepatectomies were performed as described by Greene and Puder, with minor modifications. 2o
Briefly, anesthesia was initiated and maintained with isoflurane (2% with 2L1min O2 flow). A
vertical midline incision was made in the skin of the abdomen from the xiphoid cartilage extending
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to the midabdomen. The falciform ligament above the median lobe was cut just proximal to the
superior vena cava. The left lateral and median lobes were ligated with 4-0 silk and cut away
from the liver using microsurgery scissors. Mice were anesthetized with ketaminelxylazine

(1000/15 mglkg, i.m.) at time of sacrifice.

Histology
The capacity of liver regeneration was assessed by proliferating-cell-nuclear-antigen
(PCNA) staining in Ding et al (in publication). PCNA staining employed a monoclonal mouse antiPCNA clone PC10 (Dako, Glostrup, Denmark) and a peroxidase-linked secondary antibody and
diaminobenzidine (ARK peroxidase for mouse primary antibodies, DAKO, Carpinteria, CA). Cell
cycle progression (per 1,000 hepatocytes) was estimated via PCNA staining as described
Iy. 21
.
prevIous

Enzymatic assay for aldehyde dehydrogenases
Liver samples for total ALDHs activity were homogenized in RIPA buffer [20 mM Tris/CI,
pH 7.5,150 mM NaCI, 1 mM EDTA, 1 mM EGTA, 1% (w/v) Triton X-100], containing protease
and phophatase inhibitor cocktails (Sigma, St. Louis, MO). Mitochondrial protein for the ALDH2
activity assay was extracted from the liver, as described by Wiekowski et al.

22

This work was

performed by Ding et al (in publication).

Perfusion and hepatocyte isolation
A vertical midline incision was made in the skin of the abdomen from the xiphoid cartilage
extending to the midabdomen. The inferior vena cava (IVC) was exposed and a 20G catheter
was inserted into the vein. Ethylene glycol tetraacetic acid (EGTA) solution was perfused through
the liver at a rate of 5 mLlmin and the portal vein was cut to allow the perfusion fluid to exit the
liver. Immediately following the cutting of the portal vein the chest cavity is opened and the
suprahepatic IVC was clamped. EGTA solution was perfused through the liver (5 mLlmin) for 5
minutes under a heat lamp. Following the EGTA solution, a collagenase solution containing
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collagenase D will be perfused through the liver for 8 minutes under a heat lamp. All perfusates
were kept at 40°C prior to perfusion through the liver. Following the perfusion with collagenase
solution containing collagenase D, the liver was removed and minced in media on ice. The cells
were filtered through a sterile BD Falcon nylon cell strainer (70 IJm) and placed in a 50 mL
polypropylene conical tube. The tube was spun in a centrifuge at 400 rpm for 5 min at 4°C. The
supernatant was removed and hepatocytes were resuspended in Hanks Balanced Salt Solution
(HBSS) and Percoll Solution and spun at 400 rpm for 20 minutes at 4°C. The supernatant
following this spin was removed prior to suspending the remaining hepatocytes in HBSS and
spun again at 400 rpm for 5 minutes at 4°C 2 times. An aliquot was taken prior to the second
spin and cell viability was assessed using Trypan blue staining of dead cells. Perfusions
performed in which cell viability was less than 85% were not included in supplemental
experimental steps.

Cellomics Analysis
Hepatocytes were seeded on a 96-well plate at 10,000 cells/well in 100 IJL of media and
incubated at 3rC in 5% CO 2 for 24 H to allow attachment of the cells to the plate. For the Alda-1
experiments, hepatocytes were preincubated with Alda-1 (1.52 IJM) and/or Daidzin (60 IJM) for 1
H prior to exposure to 4-HNE from 4 to 24 H. 4-HNE is a lipid aldehyde that is a major product of
lipid peroxidation and is toxic to cells.
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The concentration of Alda-1 used for the experiments

was determined by performing a series of dose range finding studies. After the exposure period
the media was removed and media containing dyes to assess cell function: Hoechst (nuclear
area), TMRM (mitochondrial membrane potential), and TOTO-3 (plasma membrane permeability)
were added. The plate was assessed via the Cellomics Array Scan HCS (Pittsburgh, PA).

Statistical analyses
Summary data are means ± SEM. One-way analysis of variance (ANOVA) ANOVA with
Bonferroni's post-hoc test or the Mann-Whitney rank sum test was used for the determination of
statistical significance among treatment groups, as appropriate. a, p < 0.05 compared to MD
control; b, p < 0.05 compared to MD control of the same time point after PHx.
6

RESULTS

Method Development

The first phase of our method development involved generating a protocol for hepatocyte
isolation that yielded greater than 85% viability. The 85% viability threshold was established from
previous literature on murine hepatocyte isolation. 23 ,24 We chose to analyze hepatocytes that
were incubated no longer than 48 H based on literature that noted altered hepatocyte function
and morphology approximately 4 days after isolation. 25 ,26,27 The hepatocytes were plated at a
density of 10,000 cells/well in 96-well plates based on experiments performed in the laboratory
employing the Cellomics HCS.
Initial experiments performed with the Cellomics HCS used factory recommended
fluorescent dye concentrations as follows: Hoechst (0.8 I-IM), TMRM (0.020 I-IM), TOTO-3 (1 I-IM)
and Flou-4 (1 I-IM). It is imperative to have a well-defined nuclear area, because all Cellomics
HCS acquisition data are determined from the presence of a nucleus. In our initial experiment the
Cellomics HCS was unable to acquire nuclei because the concentration of Hoechst in the media
was too low. This was a result of the hepatocytes' ability to export Hoechst by an ABC
transporter.

28

To counter the efflux of Hoechst we experimented with multiple concentrations of

Hoechst dye and determined that a final concentration of 12.5 I-IM Hoechst would be used for all
experiments discussed in the results. Additionally, we found that Flou-4 (excitation 475 nm and
emission 515 nm) could not be evaluated because of the high background created from
flavonoids (excitation 468 nm and emission 525 nm) present in the hepatocyte plasma
membrane. 29 Based on this information and the excitation and emission parameters from the
other fluorescent dyes we elected to remove this dye from our analyses.
The next step was to determine a test compound to evaluate if ALDH2 modulation could
alter hepatocyte toxicity. 4-HNE has been associated with several hepatic diseases, is a product

7

30
of oxidative stress in the liver, and is a known inactivator of ALDH2. ,31 Additionally, 4-HNE was
an endpoint for the evaluation of Alda-1 which was used to enhance ALDH2 activity.32 Early
experiments employed a 96-well plate design with a serial dilution (1 :2) of 4-HNE ranging from 1
mM down to 1.9 IJM and control wells (0 IJM). This range allowed us to show a range from no
effect (0 IJM) through total hepatocyte killing (500 IJM).
Alda-1 is a small-molecule activator of ALDH2 which was developed in the Mochly-Rosen
Laboratory.32 Based off of the methods from the Mochly-Rosen Laboratory, we selected a range
of concentrations to pursue that encompassed all of the test concentrations previously used. 32 ,33
We determined that in our hands a concentration of 1.52 IJM Alda-1 was the most efficient
concentration. As the concentration increased, we saw no additive effect on protection and an
increasing amount of background fluorescence.
Daidzin, which inactivates ALDH2, was also incubated with hepatocytes to determine if it
would blunt Alda-1 protection or increase cell death at lower concentrations of 4-HNE. Daidzin
had previously been used in experiments with Alda-1 and was found to have an overlapping
binding site near the exit of the substrate tunnel.

33

After searching the literature we determined

that a concentration of 60 IJM of Daidzin was appropriate for the purpose of the experiments. 33 ,34
Following the development of the techniques mentioned above we were able to perform
our experiments. The isolation and initial incubation of hepatocytes was similar regardless of the
method by which we activated ALDH2. EtOH pretreatment was performed prior to hepatocyte
isolation and the addition of Alda-1 and Daidzin pretreatment was performed in vitro for the
respective experiments. Addition of 4-HNE was identical regardless of pretreatment method.
Analyses were performed using a protocol developed on the Cellomics HCS during the
developmental phase.

Increasing ALDH2 activity with Alda-1 protects hepatocytes
Because Alda-1 is a known ALDH2 activating compound, increased ALDH2 activity
should protect against exposure to higher concentrations of 4_HNE.
4-HNE were tested to evaluate hepatocyte function.

8
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Multiple concentrations of

Mitochondrial membrane potential (TMRM fluorescence) was decreased in hepatocytes
exposed to 4-HNE levels above 125 IJM. Cell membrane permeability (TOTO-3 flourescence)
was increased in hepatocytes treated with 125 and 250 IJM 4-HNE. At 24 hours after 125 and
250 IJM 4-HNE addition, there is significantly increased mitochondrial membrane potential
(TMRM fluorescence) in hepatocytes pretreated with 1.52 IJM Alda-1 (Fig. 3) .. Additionally, cell
membrane permeability (TOTO-3 fluorescence) was significantly decreased in hepatocytes
pretreated with 1.52 IJM Alda-1 prior to 4-HNE exposure at 125 and 250 IJM. Representative
photomicrographs (Fig. 4) of hepatocytes exposed to 250 IJM of 4-HNE are presented as well.
Basal levels of mitochondrial membrane potential (red) and cell membrane permeability (green)
are presented in the control photomicrograph. At 250 IJM 4-HNE, hepatocytes have low
mitochondrial membrane potential but increased cell membrane permeability. Alda-1 (1.52 IJM)
in the presence of 250 IJM 4-HNE was able to rescue mitochondrial membrane potential and
blunt cell membrane permeability.
Approximately 81% of cells pretreated with Alda-1 had normal mitochondrial membrane
potential (>200 AU) and low plasma membrane permeability «200 AU). This is contrasted with
41 % of cells exposed to 4-HNE meeting the same criteria (Fig. 5).
Decreasing ALDH2 activity with Daidzin enhances hepatocyte death
Daidzin is a known ALDH2 inhibitor that was employed to determine if we could block the
protective effect of Alda_1.

35

Multiple concentrations of 4-HNE were tested and the

predetermined concentration of Alda-1 (1.52 IJM) was coincubated with Daidzin (60 IJM) prior to
the 4-HNE exposure.
Mitochondrial membrane potential following 24 H incubation with 125 and 250 IJM 4-HNE
in the presence of Alda-1 and Daidzin was significantly increased compared to controls on
average. Interestingly, at a 250 IJM concentration of 4-HNE the protective effect of Alda-1 was
significantly blunted in the presence of Daidzin (Fig. 3). Cell membrane permeability was
significantly decreased compared to the control group at 125 and 250 IJM HNE incubations,
however, the protection was significantly blunted when compared to hepatocytes pretreated with
Alda-1 alone.
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The individual hepatocyte data showed no difference between Alda-1 and the Daidzin
plus Alda-1 groups alone (Fig. 5). However, in the presence of 250 IJM 4-HNE 81 % of
hepatocytes had normal function in the Alda-1 group compared to 65% of hepatocytes in the
Daidzin plus Alda-1 group.
Administration of EtOH prior to hepatocyte isolation protected hepatocytes from 4-HNE
toxicity
Mice were pretreated with EtOH prior to hepatocyte isolation to further explore the
enhanced regeneration observed by this treatment previously. Multiple concentrations of 4-HNE
were tested following the acute EtOH pretreatment period.
Mitochondrial membrane potential was decreased and cell membrane permeability was
increased in control hepatocytes following 24 H exposure to 125 IJM 4-HNE (Figs. 6 and 7).
Hepatocytes isolated from animals pretreated with EtOH were protected from the effects of 125

IJM 4-HNE. Approximately 30% of hepatocytes from the control group were in a stage of cell
dysfunction (i.e., <200 AU TMRM or >200 AU TOTO-3 flourescence) following 24 H incubation
with 4-HNE while only 18% fit this criteria from the EtOH pretreatment group.

10

DISCUSSION

The liver has tremendous ability to regenerate, however this regenerative ability is
inhibited in fibrosis and cirrhosis. Our lab has shown that acute EtOH administration enhanced
hepatic regeneration following PHx. These results led us to look more closely at ALDH2, which is
key to the final step in EtOH oxidation. Lipid peroxides, which cause oxidative stress, are a
product of PHx and are metabolized by ALDH2. Our results suggested that ALDH2 played an
important role in mitigating the oxidative stress caused by PHx, thus protecting hepatocytes from
further injury and enhancing the regenerative ability of the liver.
To further explore this mechanism we employed Cellomics HCS which allowed us to look
at several endpoints in isolated mouse hepatocytes (e.g. mitochondrial membrane potential and
cell membrane integrity). The first goal was to show that by enhancing ALDH2 activity with
Alda-1 we could protect hepatocytes from 4-HNE, a lipid peroxide. Next, we also wanted to show
that addition of Daidzin (ALDH2 inactivator) could blunt the protective effect of Alda-1. Lastly, we
wanted to see if the protection from acute EtOH could be replicated in the in vitro setting.
A method for evaluating primary hepatocytes with the Cellomics HCS was adapted from
techniques the lab already was familiar with (i.e. liver perfusion, hepatocyte isolation, and cell
culture) and a paper by O'Brien et al which evaluated HepG2 cell toxicity with the Cellomics
HCS.
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We found that setting up 10,000 cells/well on 96-well plates was able to provide a

monolayer to be analyzed with the Cellomics HCS. Additionally, we determined that in primary
hepatocytes Hoechst, TOTO-3, and TMRM fluorescent dyes could be analyzed but Flou-4 was
not used due to high background from autofluorescence generated from the hepatocytes.

36

Lastly, we were able to determine appropriate concentrations of 4-HNE, Alda-1 and Daidzin to
use in our experimental design.
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The Cellomics HCS data here supported the initial hypothesis and showed a protective
effect of Alda-1 when exposed to 4-HNE. At the well level as illustrated in Fig. 3, mitochondrial
membrane potential was protected and cell membrane permeability was blunted when
hepatocytes were pre-treated with Alda-1. These effects were also carried through to the
individual cell data. These data help to illustrate the depth of analyses available with the
Cellomics HCS. While the well data was able to show protection, the cell level data allows us to
evaluate multiple parameters against one another. For example, we can see that the
mitochondrial membrane potential begins to decrease before increase in cell membrane
permeability (Figs. 5 and 6). This gives us insight into the mechanism behind cell death; which as
expected was a result of mitochondrial injury from 4-HNE exposure.

37

Co-incubation of Alda-1 and Daidzin impaired the protective effect of Alda-1 when
hepatocytes were exposed to 4-HNE. Daidzin did not completely ablate the Alda-1 effect but
there was a Significant decrease in the mitochondrial membrane potential and increase in cell
membrane permeability. This effect was seen not only at the well level but also at the individual
cell level. The cell level data shows that again mitochondrial function was decreased prior to cell
death. Because the binding site for Daidzin on ALDH2 overlaps the binding site for Alda-1, higher
concentrations of Daidzin may lead to even further blunting of the Alda-1 protection.
Finally, although not as strong an effect, we were able to show some protection of acute
EtOH pretreatment from 4-HNE toxicity. Cell death was mediated first by a loss in mitochondrial
function and then a loss in membrane integrity. This is further confirmation that by enhancing
ALDH2 activity we can protect mitochondrial function and in turn protect cell viability. EtOH
increases ALDH2 activity by going through the intermediate step of PKC£ activation, which in turn
phosphorylates ALDH2, thereby increasing the activity of the enzyme.
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.

Others have shown

that if PKC£ is not stimulated by sustained EtOH administration then the protection it affords is
lost over time.

40

.41

This may account for the less dramatic protection of acute EtOH pre-treatment

in the Cellomics HCS experiments. These results show that by increasing the activity of ALDH2,
4-HNE toxicity can be blunted.
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Although this research was performed in hepatocytes, ALDH2 is expressed at high levels
in multiple tissues (i.e. brain, lung, and heart).42 Suggesting that the protective effect ALDH2
activation provides from 4-HNE toxicity may also apply to these tissues. Indeed, the initial work
with Alda-1 was performed in an ischemiaireperfusion model in rat hearts.
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This work showed

that by enhancing ALDH2 activity, rat hearts were protected from the ischemic injury.
Importantly, the protective effect was linked to increased 4-HNE metabolism by ALDH2.
Recently, the same group showed that a topical application of Alda-1 reduced the severity and
delayed the onset of dermatitis resulting from irradiation.
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Again in this model, 4-HNE adducts

were significantly decreased in the skin of the mice. These data show the utility of ALDH2
activation in multiple tissues and the protection afforded from increased 4-HNE metabolism.
It is becoming clear that individuals with the ALDH2*2 polymorphism are more
susceptible to various diseases.

44

Indeed, a link has been established between the ALDH2*2

polymorphism and increased risk for developing Alzheimer's Disease.
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The authors again

suggest that the inability to metabolize 4-HNE may playa causal role in the development of
Alzheimer's Disease. This suggests that the higher incidence of Alzheimer's Disease in
individuals with the ALDH2*2 polymorphism may be prevented by increasing the activity of the
mutant ALDH2. Recently, Shea and Remington argued that we are intervening too late in the
development of Alzheimer's Disease.
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Perhaps increasing the activity of ALDH2 in populations

susceptible to the disease, prior to the onset of the disease, will decrease the incidence rate.
Taken together, these results show the possible utility in increasing the activity in ALDH2
to protect against various diseases. The mechanisms all link metabolism of 4-HNE (resulting
from oxidative stress) by ALDH2 to protecting against the progression of the respective malady
(Fig. 8). While most of the work discussed above links the ALDH2*2 polymorphism with
increased incidences of disease, there may be therapeutic utility for the increased activity in
ALDH2 wild-type individuals. For example, the Alda-1 experiments discussed above used
animals which had the wild type ALDH2 enzyme. A possible therapeutic effect was suggested in
the skin irradiation experiment for individuals exposed to high levels of radiation. If a therapeutic
effect of increased ALDH2 activity is confirmed then this could provide a therapy for several
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maladies (e.g. ALD, Alzheimer's Disease, Myocardial Infarction). Thus, increasing ALDH2
activity may prove a useful tool in prevention and/or treatment of various chronic disease states.
Further experiments should be performed to verify the findings presented in this
document. An ALDH2 knockout mouse has been developed and used previously in published
reports. 47 .48 Hepatocytes from these knockout mice should be isolated and analyzed employing
the methods designed here. From these follow up experiments we could determine if 4-HNE
toxicity is increased in hepatocytes lacking ALDH2. Additionally, we could further confirm that
Alda-1 protection is mediated through ALDH2 activation. Lastly, Daidzin inactivates ALDH2 and
should therefore have no effect in ALDH2 knockout mice. The collection of these data would help
to further strengthen the case that ALDH2 is key to enhancing hepatocyte viability.
Second, in order to verify our hypothesis that ALDH2 activation by acute EtOH
administration protects hepatocytes from 4-HNE toxicity we could again employ the ALDH2
knockout mice. If our model is correct then no protection would be afforded to hepatocytes from
these mice following acute EtOH treatment. Additionally, these mice could be used in the PHx
model to evaluate liver regeneration following acute EtOH administration. At the present time no
research has been done to characterize liver regeneration in ALDH2 knockout mice (PubMed
search using the terms: ALDH2, knockout, liver and regeneration). By performing these
experiments we could further understand the role of ALDH2 in protecting hepatocytes from 4HNE toxicity and determine what effect the lack of ALDH2 has on liver regeneration (in MD and
EtOH pretreated mice).
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SUMMARY AND CONCLUSIONS

The final phase of ALD results in fibrosis and cirrhosis, which cause impaired hepatic
regeneration. Currently there is no therapy to prevent or reverse the disease. Through further
study of the disease and its mechanisms a viable therapy can be developed. To that end, the lab
looked to evaluate the effects of acute EtOH on hepatic regeneration. It is well known that
chronic EtOH administration impairs hepatic regeneration. The finding that acute EtOH enhanced
hepatic regeneration was very interesting and found to be associated with an increase in ALDH2
activity.
Cellomics HCS has previously been used by O'Brien et al. to show high specificity and
selectivity for toxic compounds in HepG2 cells. This showed that the Cellomics HCS was indeed
a very powerful tool to understand hepatotoxicity in the liver. We in turn developed a method
using primary hepatocytes in the Cellomics HCS that allowed us to assess mitochondrial function
and cell membrane permeability in these cells. We then used the method to expose hepatocytes
to 4-HNE while modulating ALDH2 activity. We found that increasing ALDH2 activity with either
Alda-1 or acute EtOH pretreatment protected mitochondrial membrane potential and cell
membrane integrity. Additionally by impairing ALDH2 with Daidzin we were able to blunt the
protective effect of Alda-1 .
At this time there is no therapy to enhance hepatic regeneration in ALD. These data
suggest that by increasing ALDH2 activity we can decrease oxidative stress. By decreasing
oxidative stress perhaps we can halt or even reverse the progression of ALD. ALDH2 activation
has shown promise in protecting against other injuries that result in oxidative stress as well
(ischemia/reperfusion and irradiation) which shows applications outside of ALD. Additionally,
increasing ALDH2 activity may be a therapeutic target for other diseases (e.g. NAFLD and
Alzheimer's Disease); indicating utility for the enzyme far beyond the scope of this research.
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Fig. 4: Representative composite photomicrographs (20x) depicting
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Nuclear fluorescence (Hoechst; blue), mitochondrial membrane potential (TMRM;
red), and cell membrane permeability (TOTO-3; green).
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